Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alliance Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: All Mtn Ski who wrote (531)	6/15/2002 3:28:06 PM
From: John R Resseger	Read Replies (1) \| Respond to of 548

OxygentTM News OxygentTM, Alliance's intravascular oxygen carrier ("blood substitute"), will be featured in a segment of the television program "Next Frontiers: Health & Technology" scheduled to air this Sunday at 8pm and 11pm EDT on the Discovery Health Channel. Please see the Discovery Health TV Schedule for additional information and check your local listings to confirm the date and time in your area. In addition, Oxygent will be discussed in an article in the June 24 issue of Newsweek magazine, which will be on the newstands starting June 17. Alliance's David Klein, Ph.D., Senior Vice President, Research and Development, and Peter Keipert, Ph.D., Program Director, Oxygen Carriers Development, were among those interviewed for the television and magazine reports. Oxygent (perflubron emulsion) was also discussed at recent scientific and medical conferences in the U.S. and abroad. Information about the product and data from clinical studies showing that the use of Oxygent reduced the need for donor blood during surgery were presented by Dr. Keipert as well as Simon Faithfull, MD, Ph.D., Vice President, Medical Affairs Development, and several Oxygent investigators. These conferences included the Oxygen Therapeutics and Transfusion Alternatives Conference organized by the American Association of Blood Banks in Washington, DC, the Consensus Conference on Artificial Oxygen Carriers sponsored by the Royal College of Physicians in Edinburgh, Scotland, the International Symposium on Blood Substitutes in Stockholm, Sweden, the Conference on Clinical Transfusion Practice sponsored by the National Blood Service in Birmingham, UK, the Digestive Diseases Week Conference in San Francisco, the Network for Advancement of Transfusion Alternatives 3rd Annual International Symposium in Rome, Italy, and the American Society of Clinical Pathology "Future Trends in Transfusion Medicine" Teleconference, which was broadcast in the US, Canada, and Europe. Preclinical studies that demonstrated the oxygenation benefits of Oxygent have also been addressed at recent meetings. A study entitled, "Perflubron Emulsion Increases Subcutaneous Tissue Oxygen Tension" was discussed at the Wound Healing Society 12th Educational Symposium in Baltimore by Dr. Noah A. Rosen of the Department of Surgery, Boston University Medical Center. The study was conducted by Dr. Rosen and collaborators at the Wound Healing Research Laboratory at the University of California at San Francisco. Another study, "Perflubron Emulsion (Oxygent) - A Novel Therapeutic Option for Enhancing Microcirculation in Acute Pancreatitis" was presented by Dr. Thomas Foitzik of Chirurgische Klinik 1, Freie Universitat-Berlin at the Annual Meeting of the German Surgical Society in Berlin. Oxygent is being developed by Alliance in the United States, Canada, and Europe in conjunction with Baxter Healthcare Corporation. As announced previously, the companies are preparing to launch a new pivotal European Phase 3 study involving general surgery patients undergoing various procedures that typically require transfusion of donor blood.